Sentences with phrase «in treating lung cancer»

«CRKII most likely regulates the stability of mutated epidermal growth factor receptors and drives cancer growth by promoting signaling, or communication, within cancer cells,» said Julia Petschnigg, lead author on the paper and a postdoctoral fellow at U of T. «We found that a combinatorial chemotherapy that inhibits those mutated receptors and CRKII could be beneficial in treating lung cancer.»

Pembrolizumab, or pembro, an immunotherapy drug that unmasks cancer cells and allows the body's own immune system to help destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America ® (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona.

Not exact matches

They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell lung cancer in patients with a certain genetic mutation.

Juno also has a few other compounds in early stages of development aimed at treating NHL, pediatric ALL, multiple myeloma, ovarian & breast cancer, AML, lung cancer, and more.

«Indeed, in a second tumor model of metastatic breast cancer, we demonstrated that mice treated with the EphA2 - targeting paclitaxel conjugate presented nearly no lung metastases, while a large numbers of lesions were observed in both untreated mice and in mice treated with just paclitaxel.»

«One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that's been treated previously with radiation treatment,» said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist.

The modified toxin could treat asthma, in which lung cells secrete too much mucus, and cancers in which cells overproduce cytokines.

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

«In the 20 years that I've been in practice, I consider this a major milestone,» she adds, noting that the trial results helped achieve U.S. Food and Drug Administration approval in March to treat such patients whose lung cancer progressed, despite standard chemotherapIn the 20 years that I've been in practice, I consider this a major milestone,» she adds, noting that the trial results helped achieve U.S. Food and Drug Administration approval in March to treat such patients whose lung cancer progressed, despite standard chemotherapin practice, I consider this a major milestone,» she adds, noting that the trial results helped achieve U.S. Food and Drug Administration approval in March to treat such patients whose lung cancer progressed, despite standard chemotherapin March to treat such patients whose lung cancer progressed, despite standard chemotherapy.

Her experience led her to become a radiation oncologist, and she now works at M.D. Anderson Cancer Center in Houston, Texas, treating lung cCancer Center in Houston, Texas, treating lung cancercancer.

In addition, the study showed that the 5 - year survival rate for selected older patients with advanced lung cancer who were treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

To demonstrate the potential for treating lung disease, the researchers used the nanoparticles to block two genes that have been implicated in lung cancer — VEGF receptor 1 and Dll4, which promote the growth of blood vessels that feed tumors.

The study, called «Molecular Determinants of Drug - Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patieLung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patCancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patielung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patcancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.

In a letter published in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapIn a letter published in the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapin the cancer journal Annals of Oncology, researchers led by Professor Jean - Philippe Spano, head of the medical oncology department at Pitie - Salpetriere Hospital AP - HP in Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapin Paris, France, report that while treating an HIV - infected lung cancer patient with the cancer drug nivolumab, they observed a «drastic and persistent decrease» in the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapin the reservoirs of cells in the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapin the body where the human immunodeficiency virus (HIV) is able to hide away from attack by anti-retroviral therapy.

Nivolumab is PD - 1 inhibitor, which is used to treat several cancers in their advanced stages, including melanoma, non-small cell lung cancer and kidney cancer.

Dr. Timmerman, who holds the Effie Marie Cain Distinguished Chair in Cancer Therapy Research, has championed the use of SABR globally and has served as the lead investigator in several national trials designed to evaluate the efficacy and safety of SABR to treat cancer in the lung, liver, spine, and proCancer Therapy Research, has championed the use of SABR globally and has served as the lead investigator in several national trials designed to evaluate the efficacy and safety of SABR to treat cancer in the lung, liver, spine, and procancer in the lung, liver, spine, and prostate.

This week it emerged that the first human test of the controversial gene - editing technique CRISPR had taken place at West China Hospital in Chengdu, where oncologists used it to treat a man with an aggressive lung cancer.

«Molecule designed to treat lung cancer shows promising results in mice.»

In a study appearing in Science Translational Medicine, the researchers report they have effectively and safely employed this stem cell - targeting system in mice to treat metastatic breast cancer that had spread to the lunIn a study appearing in Science Translational Medicine, the researchers report they have effectively and safely employed this stem cell - targeting system in mice to treat metastatic breast cancer that had spread to the lunin Science Translational Medicine, the researchers report they have effectively and safely employed this stem cell - targeting system in mice to treat metastatic breast cancer that had spread to the lunin mice to treat metastatic breast cancer that had spread to the lung.

«This work suggests that we need to tease out the mechanisms by which COPD may increase lung cancer risk in smokers, and to conduct clinical trials to determine whether treating COPD in former and current smokers lessens that risk,» said David Christiani, Elkan Blout Professor of Environmental Genetics at Harvard Chan School and senior author of the study.

«Historically, when treating early lung cancer with radiotherapy, progression at the site of the primary tumor was the most common failure resulting in suffering and death,» said lead study author Robert Timmerman, MD, professor and vice chair of the department of radiation oncology at the University of Texas Southwestern Medical Center in Dallas.

Previous work at CU Cancer Center shows these drugs are especially useful against lung cancers that over-express both EGFR and HER2, implying that in addition to targeting HER2 - positive lung cancers with drugs approved to treat HER2 - positive breast cancers, there may be a role for HER2 inhibitors in HER2 cancers, perhaps both breast and lung.

«In this study, outcomes for HER2 - positive lung cancer patients treated with conventional therapies were similar to outcomes for HER2 - negative patients treated in the same waIn this study, outcomes for HER2 - positive lung cancer patients treated with conventional therapies were similar to outcomes for HER2 - negative patients treated in the same wain the same way.

And the over-the-counter drug cimetidine, which inhibits acid production in the stomach and is used to treat heartburn, matched a certain type of lung cancer.

With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online today in The Annals of Thoracic Surgery.

November 14, 2006 Anti-cancer drug shows early promise in pulmonary hypertension A drug used to treat kidney cancer can prevent the development of pulmonary hypertension (high blood pressure in the lungs) in rodents, report researchers from the University of Chicago at the 2006 annual meeting of the American Heart Association, November 12 to15, in Chicago.

Pembrolizumab, in particular, has been used to treat melanoma, non-small cell lung cancer, and in some cases, head and neck cancers.

As a result, the mice had twice as many cancer cells zipping through their bloodstream and in their lungs compared with mice not treated with paclitaxel.

The purpose of this study is to compare the effectiveness of daratumumab in combination with atezolizumab against atezolizumab alone in patients who have advanced non-small cell lung cancer (NSCLC) that has previously been treated.

Immunotherapy using checkpoint inhibitors has changed the way we treat several aggressive cancers such as melanoma, non-small cell lung and head & neck cancers, among others, with durable responses achieved in the metastatic setting.

Wang's team discovered that if human lung cancer cells in a lab dish in the presence of the receptor were treated with BCX, they migrated less than untreated ones.

Novel strategies that are effective in treating brain metastases in patients with lung cancer are needed.

Long - term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole - brain radiotherapy and thoracic chemoradiation.

In addition to lung cancer, our thoracic surgeons treat a variety of other lung conditions, including:

«What we see over and over in trying to treat some of the most aggressive and intractable cancers, including many lung, brain, ovarian, breast, melanoma and sarcoma tumors, is that the tumor fights back.

The European Lung Cancer Conference (ELCC) is the reference event in Europe for professionals treating lung cancLung Cancer Conference (ELCC) is the reference event in Europe for professionals treating lung canclung cancers.

Combining physical and biologic parameters to predict radiation - induced lung toxicity in patients with non-small-cell lung cancer treated with definitive radiation therapy.

In the US, PD - 1 and PD - LI inhibitors have been approved to treat some types of lung cancer, kidney cancer, and Hodgkin's lymphoma.

LA JOLLA, CA — Drugs targeting an enzyme involved in inflammation might offer a new avenue for treating certain lung cancers, according to a new study by scientists at the Salk Institute for Biological Studies.

10/7/2008 Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaccLung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaCancer Vaccine Trial Launched at Moores UCSD Cancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaCancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaCancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vacclung cancer by treating patients with a novel kind of cancer vacancer by treating patients with a novel kind of cancer vacancer vaccine.

But I very well likely will be treating them in five years — and that's a new story for lung cancer.»

In some cases, surgeons have successfully treated such limited cancer spread, producing long - term survival by removing the primary cancer and one or two distant tumors, off - shoots of the original cancer — usually in the lung or liveIn some cases, surgeons have successfully treated such limited cancer spread, producing long - term survival by removing the primary cancer and one or two distant tumors, off - shoots of the original cancer — usually in the lung or livein the lung or liver.

There is no typical story because when a person is diagnosed with lung cancer today, I don't know what I'm going to be treating them with in five years.

Dr Lesley Walker, Cancer Research UK's director of cancer information, said: «We've made progress in recent years to discover new ways to tackle lung cancer and this important trial brings further opportunities for this hard to treat diCancer Research UK's director of cancer information, said: «We've made progress in recent years to discover new ways to tackle lung cancer and this important trial brings further opportunities for this hard to treat dicancer information, said: «We've made progress in recent years to discover new ways to tackle lung cancer and this important trial brings further opportunities for this hard to treat dicancer and this important trial brings further opportunities for this hard to treat disease.

These drugs have been used to treat melanoma and lung cancer, and are being tested in other cancers, including ovarian cancer.

The first UK license for CRISPR / Cas9 use in editing genes in human embryos was granted in 2016, xvii and CRISPR - edited cells to treat lung cancer were administered in the world's first human trials for the technique by a Chinese group in late 2016.

Cisplatin, a commonly used chemotherapeutic reagent in lung cancer treatment (Wang and Lippard, 2005; Chattopadhyay et al., 2006), was utilized to treat the cells.

The discovery could change the approach to treating even the smallest lung cancers — the size of a pea — which are known to recur within five years in 30 to 40 percent of patients.